Drotokibart clinical trials
How each study uses drotokibart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the drotokibart studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- SHR-1819 Injection
- 8
Studies by the year they started
8 studies that test it; most in 2026 (4)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Guangdong Hengrui Pharmaceutical Co., Ltd (7) · Shanghai Hengrui Pharmaceutical Co., Ltd. (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 2 in phase 3
Studies that test drotokibart, phase 3 first.
- Dec 2026A Clinical Study Evaluating the Efficacy and Safety of SHR-1819 Injection in Patients With Seasonal Allergic RhinitisPhase 3 · Guangdong Hengrui Pharmaceutical Co., Ltd
- Nov 2027A Study of SHR-1819 Injection in Adolescents With Severe Atopic DermatitisPhase 3 · Guangdong Hengrui Pharmaceutical Co., Ltd
- Jun 2027A Study of SHR-1819 in Patients With Moderate-to-severe Atopic DermatitisPhase 2 · Guangdong Hengrui Pharmaceutical Co., Ltd
Studies
Open first, then newest update. How each study uses drotokibart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Study of SHR-1819 Injection in Adolescents With Severe Atopic DermatitisRecruitingPhase 3Guangdong Hengrui Pharmaceutical Co., LtdNCT07309055Written as SHR-1819 Injection
- Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo NodularisRecruitingPhase 2/3Guangdong Hengrui Pharmaceutical Co., LtdNCT06554509Written as SHR-1819 Injection
- A Clinical Study Evaluating the Efficacy and Safety of SHR-1819 Injection in Patients With Seasonal Allergic RhinitisActive, not recruitingPhase 3Guangdong Hengrui Pharmaceutical Co., LtdNCT07688772Written as SHR-1819 Injection
- A Clinical Study on the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of SHR-1819 Injection in Patients With Seasonal Allergic RhinitisCompletedPhase 2Guangdong Hengrui Pharmaceutical Co., LtdNCT07091357Written as SHR-1819 Injection
- A Study on the Bioavailability of SHR-1819 Injection Administered Subcutaneously Using Different Injection Devices in Healthy SubjectsCompletedPhase 1Guangdong Hengrui Pharmaceutical Co., LtdNCT07264335Written as SHR-1819 Injection
- A Phase Ib/II Study to Investigate the Safety of SHR-1819 in Children and Adolescents With Moderate-to-severe Atopic DermatitisCompletedPhase 1/2Guangdong Hengrui Pharmaceutical Co., LtdNCT06713499Written as SHR-1819 injection
- A Study of SHR-1819 in Patients With Moderate-to-severe Atopic DermatitisActive, not recruitingPhase 2Guangdong Hengrui Pharmaceutical Co., LtdNCT07321951Written as SHR-1819 Injection
- A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic DermatitisCompletedPhase 2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT06012812Written as SHR-1819 injection
Codes
What other systems call drotokibart · ClinicalTrials.gg INT033137
- UNII (FDA) FA6H9P65L6DROTOKIBARTOne source FDA
- NCI Thesaurus C211769DrotokibartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | FA6H9P65L6 | DROTOKIBART | One source FDA |
| NCI Thesaurus | C211769 | Drotokibart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.